|
1
|
Sharkey RM and Goldenberg DM: Cancer
radioimmunotherapy. Immunotherapy. 3:349–370. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carlsson J: Potential for clinical
radionuclide-based imaging and therapy of common cancers expressing
EGFR-family receptors. Tumour Biol. 33:653–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carlsson J: EGFR-family expression and
implications for targeted radionuclide therapy. Targeted
Radionuclide Tumor Therapy, Biological Aspects. Stigbrand T, Adams
G and Carlsson J: Springer Verlag; pp. 25–58. 2008, View Article : Google Scholar
|
|
4
|
Houssami N, Macaskill P, Balleine RL,
Bilous M and Pegram MD: HER2 discordance between primary breast
cancer and its paired metastasis: tumor biology or test artefact?
Insights through meta-analysis. Breast Cancer Res Treat.
129:659–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pecorino L: Molecular Biology of Cancer:
Mechanisms, Targets, and Therapeutics. Oxford University Press;
Oxford: 2005
|
|
6
|
Citri A and Yarden Y: EGF-ERBB signalling:
towards the systems level. Nat Rev Mol Cell Biol. 7:505–516. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bublil EM and Yarden Y: The EGF receptor
family: spearheading a merger of signaling and therapeutics. Curr
Opin Cell Biol. 19:124–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Morgillo F, Bareschino MA, Bianco R,
Tortora G and Ciardiello F: Primary and acquired resistance to
anti-EGFR targeted drugs in cancer therapy. Differentiation.
75:788–799. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lièvre A, Bachet JB, Boige V, Cayre A, Le
Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, et al: KRAS
mutations as an independent prognostic factor in patients with
advanced colorectal cancer treated with cetuximab. J Clin Oncol.
26:374–379. 2008.
|
|
10
|
Di Nicolantonio F, Martini M, Molinari F,
Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L,
Frattini M, Siena S and Bardelli A: Wild-type BRAF is required for
response to panitumumab or cetuximab in metastatic colorectal
cancer. J Clin Oncol. 26:5705–5712. 2008.
|
|
11
|
Nahta R and Esteva FJ: Trastuzumab:
triumphs and tribulations. Oncogene. 26:3637–3643. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Berns K, Horlings HM, Hennessy BT,
Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM,
Stemke-Hale K, Hauptmann M, et al: A functional genetic approach
identifies the PI3K pathway as a major determinant of trastuzumab
resistance in breast cancer. Cancer Cell. 12:395–402. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jathal MK, Chen L, Mudryj M and Ghosh PM:
Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.
Immunol Endocr Metab Agents Med Chem. 11:131–149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H
and Carlsson J: EGFR, HER2, and HER3 expression in laryngeal
primary tumors and corresponding metastases. Ann Surg Oncol.
15:1193–1201. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei Q, Chen L, Sheng L, Nordgren H, Wester
K and Carlsson J: EGFR, HER2 and HER3 expression in esophageal
primary tumours and corresponding metastases. Int J Oncol.
31:493–499. 2007.PubMed/NCBI
|
|
16
|
Ekberg T, Nestor M, Engström M, Nordgren
H, Wester K, Carlsson J and Anniko M: Expression of EGFR, HER2,
HER3, and HER4 in metastatic squamous cell carcinomas of the oral
cavity and base of tongue. Int J Oncol. 26:1177–1185.
2005.PubMed/NCBI
|
|
17
|
Wei Q, Shui Y, Zheng S, Wester K, Nordgren
H, Nygren P, Glimelius B and Carlsson J: EGFR, HER2 and HER3
expression in primary colorectal carcinomas and corresponding
metastases: Implications for targeted radionuclide therapy. Oncol
Rep. 25:3–11. 2011.PubMed/NCBI
|
|
18
|
Gleason DF; The Veteran’s Administration
Cooperative Urologic Research Group: Histologic grading and
clinical staging of prostatic carcinoma. Urologic Pathology: The
Prostate. Tannenbaum M: Lea and Febiger; Philadelphia: pp. 171–198.
1977
|
|
19
|
Gleason DF: Histology grading of prostate
cancer: a perspective. Hum Path. 23:273–279. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Held-Warmkessel J: Contemporary Issues in
Prostate Cancer: A Nursing Perspective. Jones & Bartlett;
Learning: pp. 107–125. 2006
|
|
21
|
Bilous M, Dowsett M, Hanna W, Isola J,
Lebeau A, Moreno A, Penault-Llorca F, Rüschoff J, Tomasic G and van
de Vijver M: Current perspectives on HER2 testing: a review of
national testing guidelines. Mod Pathol. 16:173–182. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim SJ, Uehara H, Karashima T, Shepherd
DL, Killion JJ and Fidler IJ: Blockade of epidermal growth factor
receptor signaling in tumor cells and tumor-associated endothelial
cells for therapy of androgen-independent human prostate cancer
growing in the bone of nude mice. Clin Cancer Res. 9:1200–1210.
2003.
|
|
23
|
Festuccia C, Angelucci A, Gravina GL,
Biordi L, Millimaggi D, Muzi P, Vicentini C and Bologna M:
Epidermal growth factor modulates prostate cancer cell invasiveness
regulating urokinase-type plasminogen activator activity.
EGF-receptor inhibition may prevent tumor cell dissemination.
Thromb Haemost. 93:964–975. 2005.
|
|
24
|
Scher HI, Sarkis A, Reuter V, Cohen D,
Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J and
Cordon-Cardo C: Changing pattern of expression of the epidermal
growth factor receptor and transforming growth factor alpha in the
progression of prostatic neoplasms. Clin Cancer Res. 1:545–550.
1995.PubMed/NCBI
|
|
25
|
Shah RB, Ghosh D and Elder JT: Epidermal
growth factor receptor (ErbB1) expression in prostate cancer
progression: correlation with androgen independence. Prostate.
66:1437–1444. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Festuccia C, Gravina GL, Millimaggi D,
Muzi P, Speca S, Ricevuto E, Vicentini C and Bologna M: Uncoupling
of the epidermal growth factor receptor from downstream signal
transduction molecules guides the acquired resistance to gefitinib
in prostate cancer cells. Oncol Rep. 18:503–511. 2007.
|
|
27
|
Hernes E, Fossá SD, Berner A, Otnes B and
Nesland JM: Expression of the epidermal growth factor receptor
family in prostate carcinoma before and during
androgen-independence. Br J Cancer. 90:449–454. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bartlett JM, Brawley D, Grigor K, Munro
AF, Dunne B and Edwards J: Type I receptor tyrosine kinases are
associated with hormone escape in prostate cancer. J Pathol.
205:522–529. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Morote J, de Torres I, Caceres C, Vallejo
C, Schwartz S Jr and Reventos J: Prognostic value of
immunohistochemical expression of the c-erbB-2 oncoprotein in
metastasic prostate cancer. Int J Cancer. 84:421–425. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reese DM, Small EJ, Magrane G, Waldman FM,
Chew K and Sudilovsky D: HER2 protein expression and gene
amplification in androgen-independent prostate cancer. Am J Clin
Pathol. 116:234–239. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu HL, Gandour-Edwards R, Lara PN Jr, de
Vere White R and LaSalle JM: Detection of low level HER-2/neu gene
amplification in prostate cancer by fluorescence in situ
hybridization. Cancer J. 7:395–403. 2001.PubMed/NCBI
|
|
32
|
Carles J, Lloreta J, Salido M, Font A,
Suarez M, Baena V, Nogue M, Domenech M and Fabregat X: Her-2/neu
expression in prostate cancer: a dynamic process? Clin Cancer Res.
10:4742–4745. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ady N, Morat L, Fizazi K, Soria JC,
Mathieu MC, Prapotnich D, Sabatier L and Chauveinc L: Detection of
HER-2/neu-positive circulating epithelial cells in prostate cancer
patients. Br J Cancer. 90:443–448. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Myers RB, Srivastava S, Oelschlager DK and
Grizzle WE: Expression of p160erbB-3 and p185erbB-2 in prostatic
intraepithelial neoplasia and prostatic adenocarcinoma. J Natl
Cancer Inst. 86:1140–1145. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vakar-Lopez F, Cheng CJ, Kim J, Shi GG,
Troncoso P, Tu SM, Yu-Lee LY and Lin SH: Up-regulation of MDA-BF-1,
a secreted isoform of ErbB3, in metastatic prostate cancer cells
and activated osteoblasts in bone marrow. J Pathol. 203:688–695.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gusterson B, Cowley G, Smith JA and Ozanne
B: Cellular localisation of human epidermal growth factor receptor.
Cell Biol Int Rep. 8:649–658. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Damjanov I, Mildner B and Knowles BB:
Immunohistochemical localization of the epidermal growth factor
receptor in normal human tissues. Lab Invest. 55:588–592.
1986.PubMed/NCBI
|
|
38
|
Dittadi R, Gion M, Pagan V, Brazzale A,
Del Maschio O, Bargossi A, Busetto A and Bruscagnin G: Epidermal
growth factor receptor in lung malignancies. Comparison between
cancer and normal tissue. Br J Cancer. 64:741–744. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Natali PG, Nicotra MR, Bigotti A, Venturo
I, Slamon DJ, Fendly BM and Ullrich A: Expression of the p185
encoded by HER2 oncogene in normal and transformed human tissues.
Int J Cancer. 45:457–461. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Press MF, Cordon-Cardo C and Slamon DJ:
Expression of the HER-2/neu proto-oncogene in normal human adult
and fetal tissues. Oncogene. 5:953–962. 1990.PubMed/NCBI
|
|
41
|
Gutierrez C and Schiff R: HER2: biology,
detection, and clinical implications. Arch Pathol Lab Med.
135:55–62. 2011.PubMed/NCBI
|
|
42
|
Agus DB, Sweeney CJ, Morris MJ, Mendelson
DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B,
Allison DE, Kattan MW and Scher HI: Efficacy and safety of
single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth
factor receptor dimerization inhibitor, in castration-resistant
prostate cancer after progression from taxane-based therapy. J Clin
Oncol. 25:675–681. 2007. View Article : Google Scholar
|
|
43
|
de Bono JS, Bellmunt J, Attard G, Droz JP,
Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G,
Hersberger-Gimenez V, et al: Open-label phase II study evaluating
the efficacy and safety of two doses of pertuzumab in castrate
chemotherapy-naive patients with hormone-refractory prostate
cancer. J Clin Oncol. 25:257–262. 2007.PubMed/NCBI
|
|
44
|
Solit DB and Rosen N: Targeting HER2 in
prostate cancer: where to next? J Clin Oncol. 25:241–243. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gallick GE, Corn PG, Zurita AJ and Lin SH:
Small-molecule protein tyrosine kinase inhibitors for the treatment
of metastatic prostate cancer. Future Med Chem. 4:107–119. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen L, Mooso BA, Jathal MK, Madhav A,
Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L,
Vinall RL, et al: Dual EGFR/HER2 inhibition sensitizes prostate
cancer cells to androgen withdrawal by suppressing ErbB3. Clin
Cancer Res. 17:6218–6228. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Stigbrand T, Carlsson J and Adams GP:
Developmental trends in targeted radionuclide therapy - biological
aspects. Targeted Radionuclide Tumor Therapy, Biological Aspects.
Stigbrand T, Adams G and Carlsson J: Springer Verlag; pp. 387–397.
2008, View Article : Google Scholar
|
|
48
|
Frejd YF: Novel alternative scaffolds and
their potential use for tumor targeted radionuclide therapy.
Targeted Radionuclide Tumor Therapy, Biological Aspects. Stigbrand
T, Adams G and Carlsson J: Springer Verlag; pp. 89–116. 2008,
View Article : Google Scholar
|
|
49
|
Govindan SV and Goldenberg DM: New
antibody conjugates in cancer therapy. Scientific World Journal.
10:2070–2089. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Adams GP and Weiner LM: Monoclonal
antibody therapy of cancer. Nat Biotechnol. 23:1147–1157. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gedda L, Fondell A, Lundqvist H, Park JW
and Edwards K: Experimental radionuclide therapy of HER2-expressing
xenografts using two-step targeting nuclisome particles. J Nucl
Med. 53:480–487. 2012. View Article : Google Scholar : PubMed/NCBI
|
